New hope for rare ovarian cancer: drug shrinks tumors after immunotherapy fails
NCT ID NCT07168083
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a drug called sacituzumab in 22 people with a rare and aggressive type of ovarian cancer (clear cell carcinoma) that has worsened after immunotherapy. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to see how many patients have their tumors shrink by at least 30%.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sacituzumab (SKB264)
- What this could lead to
- If it works, this could offer a new treatment option for a rare and aggressive ovarian cancer that has stopped responding to immunotherapy.
- What could go wrong
- This is a small, early-stage study with only 22 participants. The drug may not work for everyone, and side effects are possible. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY-DRUG CONJUGATES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?